Comparative Efficacy and Safety of Antibody–Drug Conjugates Versus Standard Chemotherapy in Metastatic Breast Cancer: A Comprehensive Systematic Review and Meta-Analysis
Hagar Teama, Ahmed Elnewishy, Mahmoud Noureldin, Omar Elnewishy · 2025
Read Comparative Efficacy and Safety of Antibody–Drug Conjugates Versus Standard Chemotherapy in Metastatic Breast Cancer: A Comprehensive Systematic Review and Meta-Analysis by Hagar Teama, Ahmed Elnewishy, Mahmoud Noureldin, Omar Elnewishy (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12765512.txt.
Description
Hagar Teama and co-authors pool trials of antibody drug conjugates against standard chemotherapy for spread breast cancer, in work from twenty twenty-five. Conjugates hitch a toxic drug to an antibody that homes to cancer cells, sparing the rest of the body. Their place across breast cancer subtypes needed a full tally.
Nine randomized trials with nearly thirty-five hundred patients fed the analysis. Conjugates improved overall survival and response rates over chemotherapy. Time without growth was similar, and severe side effects did not rise. Blood and gut harms ran lower, though one drug's lung risk needs watching. The authors call the class a real advance in precise treatment.
Catalog record
| CREATOR | Hagar Teama, Ahmed Elnewishy, Mahmoud Noureldin, Omar Elnewishy |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |